Formycon AG

Formycon AG is a leading independent biotechnology company headquartered in Planegg, Germany, specializing in the development of high-quality biosimilars, which are cost-effective follow-on versions of complex biopharmaceutical medicines. The company focuses on key therapeutic areas such as ophthalmology, immunology, and immuno-oncology, addressing chronic diseases like neovascular age-related macular degeneration, psoriasis, Crohn’s disease, and ulcerative colitis. Its robust pipeline features approved products including FYB201, a ranibizumab biosimilar marketed as Cimerli, Ongavia, and Ranivisio through partners like Sandoz and Teva; FYB202, a ustekinumab biosimilar known as Otulfi with Fresenius Kabi; and FYB203, an aflibercept biosimilar. Ongoing candidates encompass FYB206 targeting Keytruda for immuno-oncology and additional projects like FYB208, FYB209, and FYB210. Formycon manages the full value chain from technical development and clinical trials to regulatory approval, leveraging strategic partnerships for manufacturing and global commercialization in markets including the US, EU, Canada, and MENA regions. With around 245 employees and a history rooted in biopharmaceutical innovation since 1999, Formycon plays a pivotal role in the expanding biosimilars market by enhancing patient access to affordable biologics while driving sustainable value creation.